	US 12,472,203 B2
	Composition and method for treating hearing loss
Barry S. Seifer, Ann Arbor, MI (US); Louise A. Minor, Trinidad, CA (US); and Richard A. Detweiler, West Linn, OR (US)
Assigned to Soundbites Public Benefit Corporation, Ann Arbor, MI (US)
Filed by Soundbites Public Benefit Corporation, Ann Arbor, MI (US)
Filed on May 13, 2025, as Appl. No. 19/206,964.
Application 19/206,964 is a continuation of application No. 18/799,983, filed on Aug. 9, 2024.
Claims priority of provisional application 63/557,066, filed on Feb. 23, 2024.
Claims priority of provisional application 63/532,714, filed on Aug. 15, 2023.
Prior Publication US 2025/0268933 A1, Aug. 28, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 33/06 (2006.01); A61K 9/00 (2006.01); A61K 31/015 (2006.01); A61K 31/355 (2006.01); A61K 31/375 (2006.01); A61P 27/16 (2006.01)

CPC A61K 33/06 (2013.01) [A61K 9/0053 (2013.01); A61K 31/015 (2013.01); A61K 31/355 (2013.01); A61K 31/375 (2013.01); A61P 27/16 (2018.01)]

21 Claims

1. A method for enhancing auditory sensitivity in a human subject in need thereof, wherein the method comprises orally administering to the subject a nutraceutical formulation in the form of a suspoemulsion comprising:

i) a magnesium compound comprising salts, salt complexes or chelates thereof;

ii) Vitamin C;

iii) a provitamin A carotenoid in an amount ≥8,000 μg retinol activity equivalents (RAE);

iv) Vitamin E; and

v) a nutraceutically acceptable liquid lipophilic carrier;

wherein the molar ratio of the provitamin A carotenoid, the Vitamin C, the Vitamin E, and the magnesium compound is approximately 1:7-21:6.5-9.5:110-120, and

wherein the subject has already developed hearing loss, wherein the hearing loss is not caused by a viral infection.